GlassScriptPhysician profile
Jennifer Marie Travis
NPI 1154755692
$3,602.82
in general payments reported to CMS, 2019-2025
28 companies · $740 in 2025
The $740 reported for 2025 was more than what 98% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $696 · 2022: $716 · 2023: $863 · 2024: $588 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $459.89 | 2021-2025 | |
| Exeltis, USA INC. | $384.49 | 2021-2025 | Slynd |
| Abbvie INC. | $371.94 | 2021-2025 | |
| Astellas Pharma US INC | $271.98 | 2023-2025 | Veozah |
| Amgen INC. | $242.04 | 2021-2023 | Evenity, Prolia |
| Evofem Biosciences, INC. | $213.33 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $212.91 | 2021-2024 | |
| Shield Therapeutics INC | $193.06 | 2023-2025 | Accrufer |
| Mylan Pharmaceuticals INC. | $176.87 | 2021-2022 | |
| Exact Sciences Corporation | $145.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $129.41 | 2023 | Wegovy |
| Therapeuticsmd, INC. | $106.42 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $87.24 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $73.12 | 2021-2024 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $72.80 | 2023-2024 | Paragard T 380a, Endosee |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $64.18 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $56.60 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.04 | 2021-2023 | |
| Hologic Sales and Service, LLC | $49.42 | 2022-2025 | Aptima |
| Millicent US INC | $48.93 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Myovant Sciences INC. | $46.30 | 2021-2022 | |
| Sage Therapeutics, LLC | $34.78 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $25.51 | 2021 | |
| Axonics, INC. | $19.72 | 2022 | |
| Lilly USA, LLC | $17.60 | 2025 | Mounjaro, Zepbound |
| Vivus LLC | $17.27 | 2024 | Pancreaze |
| Radius Health, INC. | $14.46 | 2023 | |
| Aspira Women'S Health INC | $11.62 | 2023 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.